Across TCGA pan-cancer cohorts, DUS4L mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of DUS4L’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where DUS4L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DUS4L is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.
HNSC and LSCC are the cancer types where DUS4L tumor–normal differential expression is most reproducible.